Targeted Lung Cancer Drug Aces Confirmatory Trial in Frontline Setting

(MedPage Today) -- CHICAGO -- An oral targeted drug reduced the risk of disease progression or death by 35% compared with chemotherapy when given as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertions...
Source
MedPage Today
Opens original article in a new tab



